By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MolecularHealth today said that it has signed a five-year deal with the US Food and Drug Administration to evaluate and refine the firm's software system for mechanism-based drug safety assessment and prediction.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.